# Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review

## TL;DR

This paper reports two cases where dupilumab successfully treated a rare skin condition called lichenoid amyloidosis, which is difficult to manage with standard treatments.

## Contribution

The novelty lies in demonstrating dupilumab's effectiveness for treating refractory lichenoid amyloidosis, a subtype of primary cutaneous amyloidosis.

## Key findings

- Two patients with refractory lichenoid amyloidosis showed significant improvement after dupilumab treatment.
- Literature review supports dupilumab's potential as a therapeutic option for primary cutaneous amyloidosis.
- Dupilumab targets IL-4/13 pathways, relevant to type 2 inflammation seen in PCA.

## Abstract

Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.